Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | THRB | P10828 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770865 | 0.89 | ALDH1A1 (0.44) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL29770867 | 0.89 | ALDH1A1 (0.44) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL3971073 | 0.86 | MAPT (0.47) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL3498006 | 0.83 | GRM6 (0.58) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL14876133 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL3498934 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL29720422 | 0.80 | GAA (0.49) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL28892519 | 0.80 | POLB (0.49) | ALDH1A1LMNATHRBHTTHPGD | |
| SCHEMBL14965084 | 0.79 | ALDH1A1 (0.60) | ALDH1A1LMNATHRBHTTGAA | |
| SCHEMBL29720475 | 0.79 | LMNA (0.67) | ALDH1A1LMNATHRBHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309015-A1 | Methods for the Treatment of Fibrotic Disease | SHY THERAPEUTICS, LLC | 2024-09-19 | — | — | US | disclosed |
| US-20240124483-A1 | Methods for the Treatment of Fibrotic Disease | SHY THERAPEUTICS, LLC | 2024-04-18 | — | — | US | disclosed |
| EP-4284377-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| EP-4168414-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022165000-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022164997-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2021257828-A9 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124483-A1 | Methods for the Treatment of Fibrotic Disease | SMAD3, SMAD2, MAPK3 | ALDH1A1 2143/4885LMNA 987/4885THRB 1194/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | ALDH1A1 2378/4885LMNA 3970/4885THRB 1442/4885 |
| US-20240309015-A1 | Methods for the Treatment of Fibrotic Disease | SMAD3, SMAD2, MAPK3 | ALDH1A1 1929/4885LMNA 996/4885THRB 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.